Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
model for response to combination immunotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC). 2 As highlighted by
Authors
- Ji Hoon Kim (ORCID: https://orcid.org/0000-0003-3924-0434)
- Ahmed Omar Kaseb (ORCID: https://orcid.org/0000-0002-9491-0587)
- Sun Young Yim (ORCID: https://orcid.org/0000-0001-7346-5974)
- Sunyoung S. Lee (ORCID: https://orcid.org/0000-0002-5954-5991)
- Ju‐Seog Lee (ORCID: https://orcid.org/0000-0002-5666-9753)
- Sung-Hwan Lee (ORCID: https://orcid.org/0000-0003-0783-7033)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Korea University (KR)
- CHA University Bundang Medical Center (KR)
- CHA University (KR)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.3350/cmh.2024.0829
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Duncan Family Institute for Cancer Prevention and Risk Assessment
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute